Editorial for “Time‐Dependent Diffusion MRI‐Based Microstructural Mapping for Characterizing HER2‐Zero, ‐Low, ‐Ultralow and ‐Positive Breast Cancers”

Journal of Magnetic Resonance ImagingEarly View EDITORIAL Editorial for "Time-Dependent Diffusion MRI-Based Microstructural Mapping for Characterizing HER2-Zero, -Low, -Ultralow and -Positive Breast Cancers" This article relates to: Time-Dependent Diffusion MRI-Based Microstructural Mapping for Characterizing HER2-Zero, -Low, -Ultra-Low, and -Positive Breast Cancer Xiaoxia Wang, Yao Huang, Ying Cao, Huifang Chen, Xueqin Gong, Xiaosong Lan, Jiuquan Zhang, Zhaoxiang Ye, Journal of Magnetic Resonance Imaging First Published online: August 20, 2025 Simone Schiaffino, Corresponding Author Simone Schiaffino [email protected] orcid.org/0000-0003-4243-888X Imaging Institute of Southern Switzerland (IIMSI), Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland Correspondence: Simone Schiaffino ([email protected])Search for more papers by this authorAndrea Leoncini, Andrea Leoncini Imaging Institute of Southern Switzerland (IIMSI), Ente Ospedaliero Cantonale (EOC), Lugano, SwitzerlandSearch for more papers by this author Simone Schiaffino, Corresponding Author Simone Schiaffino [email protected] orcid.org/0000-0003-4243-888X Imaging Institute of Southern Switzerland (IIMSI), Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland Correspondence: Simone Schiaffino ([email protected])Search for more papers by this authorAndrea Leoncini, Andrea Leoncini Imaging Institute of Southern Switzerland (IIMSI), Ente Ospedaliero Cantonale (EOC), Lugano, SwitzerlandSearch for more papers by this author First published: 22 August 2025 https://doi.org/10.1002/jmri.70078Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookxLinkedInRedditWechatBluesky No abstract is available for this article. References 1M. Barzegar and S. Schiaffino, "Editorial for "A Channel-Dimensional Feature-Reconstructed Deep Learning Model for Predicting Breast Cancer Molecular Subtypes on Overall b -Value Diffusion-Weighted MRI"," Journal of Magnetic Resonance Imaging 59 (2024): 1436–1437, https://doi.org/10.1002/jmri.28908. 10.1002/jmri.28908 PubMed Web of Science® Google Scholar 2M. G. Davey, M. S. Davey, M. R. Boland, É. J. Ryan, A. J. Lowery, and M. J. Kerin, "Radiomic Differentiation of Breast Cancer Molecular Subtypes Using Pre-Operative Breast Imaging – A Systematic Review and Meta-Analysis," European Journal of Radiology 144 (2021): 109996, https://doi.org/10.1016/j.ejrad.2021.109996. 10.1016/j.ejrad.2021.109996 PubMed Web of Science® Google Scholar 3P. Tarantino, G. Curigliano, and S. M. Tolaney, "Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons," Cancer Discovery 12 (2022): 2026–2030, https://doi.org/10.1158/2159-8290.CD-22-0703. 10.1158/2159-8290.CD-22-0703 CAS PubMed Web of Science® Google Scholar 4P. Tarantino, E. Hamilton, S. M. Tolaney, et al., "HER2-Low Breast Cancer: Pathological and Clinical Landscape," Journal of Clinical Oncology 38 (2020): 1951–1962, https://doi.org/10.1200/JCO.19.02488. 10.1200/JCO.19.02488 CAS PubMed Web of Science® Google Scholar 5A. Bardia, X. Hu, R. Dent, et al., "Trastuzumab Deruxtecan After Endocrine Therapy in Metastatic Breast Cancer," New England Journal of Medicine 391 (2024): 2110–2122, https://doi.org/10.1056/NEJMoa2407086. 10.1056/NEJMoa2407086 CAS PubMed Web of Science® Google Scholar 6Z. Ye, X. Wang, Y. Huang, et al., "Time-Dependent Diffusion MRI-Based Microstructural Mapping for Characterizing HER2-Zero, −Low, −Ultralow and -Positive Breast Cancers" Journal of Magnetic Resonance Imaging, https://doi.org/10.1002/jmri.70074. 10.1002/jmri.70074 Google Scholar 7F. Ejima, Y. Fukukura, K. Kamimura, et al., "Oscillating Gradient Diffusion-Weighted MRI for Risk Stratification of Uterine Endometrial Cancer," Journal of Magnetic Resonance Imaging 60 (2024): 67–77, https://doi.org/10.1002/jmri.29106. 10.1002/jmri.29106 PubMed Google Scholar 8P. Tarantino, G. Viale, M. F. Press, et al., "ESMO Expert Consensus Statements (ECS) on the Definition, Diagnosis, and Management of HER2-Low Breast Cancer," Annals of Oncology 34 (2023): 645–659, https://doi.org/10.1016/j.annonc.2023.05.008. 10.1016/j.annonc.2023.05.008 CAS PubMed Web of Science® Google Scholar 9H. J. Burstein, M. R. Somerfield, D. L. Barton, et al., "Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update," Journal of Clinical Oncology 39 (2021): 3959–3977, https://doi.org/10.1200/JCO.21.01392. 10.1200/JCO.21.01392 CAS PubMed Web of Science® Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation